[go: up one dir, main page]

WO2005060996A3 - Method of altering the pka type i signalling pathway - Google Patents

Method of altering the pka type i signalling pathway Download PDF

Info

Publication number
WO2005060996A3
WO2005060996A3 PCT/GB2004/005396 GB2004005396W WO2005060996A3 WO 2005060996 A3 WO2005060996 A3 WO 2005060996A3 GB 2004005396 W GB2004005396 W GB 2004005396W WO 2005060996 A3 WO2005060996 A3 WO 2005060996A3
Authority
WO
WIPO (PCT)
Prior art keywords
pka type
altering
signalling pathway
inhibitor
ebp50
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/005396
Other languages
French (fr)
Other versions
WO2005060996A2 (en
Inventor
Kjetil Tasken
Anja Ruppelt
Mikaela Groenholm
Einar Martin Aandahl
Derek Tobin
Cathrine Carlson
Olli Carpen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lauras AS
Original Assignee
Lauras AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329869A external-priority patent/GB0329869D0/en
Application filed by Lauras AS filed Critical Lauras AS
Publication of WO2005060996A2 publication Critical patent/WO2005060996A2/en
Publication of WO2005060996A3 publication Critical patent/WO2005060996A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method of altering the PKA type I signalling pathway in a cell comprising the step of administering an inhibitor, or a molecule encoding an inhibitor, which reduces or inhibits the binding between one or more of the following binding partners: i) ezrin and PKA type I, ii) ezrin and EBP50, and iii) EBP50 and Cbp/PAG. Also provided are inhibitor molecules for use in the method of the invention and pharmaceutical compositions comprising the inhibitors. Methods of treating disorders or diseases in which abnormal PKA type I signalling occurs such as HIV, AIDS,CVI or cancer using such inhibitors are also provided.
PCT/GB2004/005396 2003-12-23 2004-12-23 Method of altering the pka type i signalling pathway Ceased WO2005060996A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0329869A GB0329869D0 (en) 2003-12-23 2003-12-23 Inhibitors
GB0329869.2 2003-12-23
US53198203P 2003-12-24 2003-12-24
US60/531,982 2003-12-24

Publications (2)

Publication Number Publication Date
WO2005060996A2 WO2005060996A2 (en) 2005-07-07
WO2005060996A3 true WO2005060996A3 (en) 2005-08-18

Family

ID=34712712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/005396 Ceased WO2005060996A2 (en) 2003-12-23 2004-12-23 Method of altering the pka type i signalling pathway

Country Status (1)

Country Link
WO (1) WO2005060996A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919063B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING LEUCOCYTE ELASTASE INHIBITOR FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919060B1 (en) * 2007-07-19 2012-11-30 Biomerieux Sa METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
AU2008285557B2 (en) 2007-07-19 2014-07-03 Biomerieux Method for the assay of liver fatty acid-binding protein, ACE and CA19-9 for the in vitro diagnosis of colorectal cancer
FR2919065B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD FOR DETERMINING APOLIPOPROTEIN AI FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2933773B1 (en) 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
WO2010059400A1 (en) * 2008-10-30 2010-05-27 The Translational Genomics Research Institute Methods and kits to identify invasive glioblastoma
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003164A1 (en) * 1986-10-28 1988-05-05 Tore Jahnsen COMPLENTARY DNA PROBES FOR HUMAN REGULATORY SUBUNITS (RIalpha AND RIIbeta) OF cAMP-DEPENDENT PROTEIN KINASES
WO1998048809A1 (en) * 1997-04-29 1998-11-05 Lauras As Use of immunomodulating agents
WO1999047150A2 (en) * 1998-03-18 1999-09-23 Institut Curie A pharmaceutical composition containing ezrin mutated on tyrosine 353
US20030049793A1 (en) * 2000-12-20 2003-03-13 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins and uses thereof
WO2003029277A2 (en) * 2001-10-03 2003-04-10 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
WO2004016739A2 (en) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003164A1 (en) * 1986-10-28 1988-05-05 Tore Jahnsen COMPLENTARY DNA PROBES FOR HUMAN REGULATORY SUBUNITS (RIalpha AND RIIbeta) OF cAMP-DEPENDENT PROTEIN KINASES
WO1998048809A1 (en) * 1997-04-29 1998-11-05 Lauras As Use of immunomodulating agents
WO1999047150A2 (en) * 1998-03-18 1999-09-23 Institut Curie A pharmaceutical composition containing ezrin mutated on tyrosine 353
US20030049793A1 (en) * 2000-12-20 2003-03-13 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins and uses thereof
WO2003029277A2 (en) * 2001-10-03 2003-04-10 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
WO2004016739A2 (en) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRDICKOVA N V ET AL: "Interaction between two adapter proteins, PAG and EBP50: a possible link between membrane rafts and actin cytoskeleton", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 507, no. 2, 26 October 2001 (2001-10-26), pages 133 - 136, XP004312034, ISSN: 0014-5793 *
DATABASE Geneseq [online] 25 July 2003 (2003-07-25), "Human phosphoprotein associated with GEMs.", XP002331867, retrieved from EBI accession no. GSN:ABR59694 Database accession no. ABR59694 *
ITOH KATSUHIKO ET AL: "Cutting edge: Negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly", JOURNAL OF IMMUNOLOGY, vol. 168, no. 2, 15 January 2002 (2002-01-15), pages 541 - 544, XP002331865, ISSN: 0022-1767 *
RECZEK DAVID ET AL: "The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 29, 17 July 1998 (1998-07-17), pages 18452 - 18458, XP002331864, ISSN: 0021-9258 *
TORGERSEN KNUT MARTIN ET AL: "Molecular mechanisms for protein kinase A-mediated modulation of immune function", CELLULAR SIGNALLING, vol. 14, no. 1, January 2002 (2002-01-01), pages 1 - 9, XP002331866, ISSN: 0898-6568 *

Also Published As

Publication number Publication date
WO2005060996A2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2005046603A3 (en) Pyridine compounds
WO2005005462A3 (en) Blys antagonists and uses thereof
NO20061080L (en) Condensed pyramidine compounds as inhibitors of voltage controlled ion channels
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2004093826A3 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
WO2006056399A3 (en) Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2005002627A3 (en) Conjugated complement cascade inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CA2672094C (en) Methods and apparatus for identifying subject matter in view data
WO2006050476A3 (en) Pyrimidine derivatives as ion channel modulators and methods of use
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2005060996A3 (en) Method of altering the pka type i signalling pathway
WO2004093816A3 (en) Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase